Disease relapse after allogeneic hematopoietic cell transplantation (alloHCT) remains the leading cause of treatment failure for patients with acute myeloid leukemia (AML), but measurable residual disease (MRD) testing after first complete remission can be a powerful predictor of relapse, according to an analysis published in *Bone Marrow transplantation*.“`html
NGS-Based MRD Assessment Predicts Outcomes in AML
Table of Contents
2025/11/30 18:22:04
NPM1 mutations are one of the most common genetic mutations in acute myeloid leukemia (AML), occurring in about 30% of adult cases.2 While current clinical guidelines for NPM1 minimal residual disease (MRD) testing often rely on measuring mutant RNA transcript levels,3 there is a continuous effort to improve the sensitivity and accuracy of testing, particularly using DNA-based next-generation sequencing (NGS) assays. Identifying patients with high-risk MRD before transplant is crucial for personalizing the conditioning regimen and posttransplant monitoring.
Pretransplant MRD defines High-Risk AML
The researchers investigated the prognostic value of a highly sensitive DNA-based NGS assay to detect mutated NPM1 in AML patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). Their findings, presented at the 65th American Society of Hematology (ASH) Annual Meeting, demonstrate that pretransplant MRD levels, as determined by this NGS assay, are strongly associated with relapse risk and overall survival.
Study Design and Key Findings
The study included 231 patients with NPM1-mutated AML who underwent alloHSCT. Patients were categorized based on their pretransplant MRD levels detected by the NGS assay:
- MRD-Negative (MRD-neg): No detectable NPM1 mutations.
- MRD-Low: Detectable NPM1 mutations,but below a predefined threshold.
- MRD-High: Detectable NPM1 mutations above the predefined threshold.
The results showed a clear correlation between MRD levels and outcomes:
- Patients with MRD-High disease had a significantly higher relapse rate compared to MRD-neg and MRD-Low patients (62% vs. 28% and 35%, respectively).
- Overall survival was also significantly shorter in the MRD-High group (median OS of 18.5 months) compared to MRD-neg (median OS not reached) and MRD-Low (median OS 38.2 months).
- Multivariate analysis confirmed that pretransplant MRD status was an independent predictor of relapse and survival,even after adjusting for other risk factors.
Implications for Clinical practice
These findings highlight the importance of highly sensitive MRD assessment using NGS prior to alloHSCT in NPM1-mutated AML. The ability to accurately identify patients with high-risk MRD allows for:
- intensified Conditioning Regimens: Patients with MRD-High disease may benefit from more intensive conditioning regimens to eradicate residual leukemia cells.
- Enhanced Posttransplant Monitoring: Closer monitoring for relapse is warranted in patients with MRD-High disease.
- Potential for Alternative Therapies: Consideration of alternative therapies, such as donor lymphocyte infusion (DLI), may be appropriate for patients with persistent or rising MRD levels posttransplant.
FAQ
Q: What is MRD?
A: Minimal residual disease (MRD) refers to the small number of leukemia cells that remain in the body after treatment. Even though these cells are not detectable by standard methods, they can lead to relapse.
Q: Why is NGS better than RNA-based MRD testing?
A: NGS offers greater sensitivity and can detect MRD even when RNA levels are low or undetectable. DNA-based assays are also less susceptible to false negatives due to RNA degradation.
Q: is this NGS assay widely available?
A: While NGS is becoming increasingly accessible, it is not yet universally available in all clinical laboratories.However,the number of labs offering NGS-based MRD testing is growing.
Key takeaways
- Pretransplant MRD assessment using highly sensitive NGS is a powerful prognostic tool in NPM1-mutated AML.
- MRD-High disease is associated with a significantly increased risk of relapse and shorter overall survival.
- NGS-based MRD results can
Related reading